An E3 Aptamer-Modified T Cell-Derived Exosomal Nanoplatform for Codelivery of Astragaloside IV and PESV: Enhancing Prostate Cancer Therapy Through Immune Modulation with Implications for Clinical Translation
International Journal of Nanomedicine · 2026-07 · Volume 21 · 1-23
DOI: 10.2147/ijn.s614400 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2026-07. Verfasst von Qing Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine Center, Shenzhen Bao'an Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen, 518…. Hauptthemen laut MEDLINE: Triterpenes, Saponins, Prostatic Neoplasms, T-Lymphocytes. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Medicine Center, Shenzhen Bao'an Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen, 518133, People's Republic of China.
- The Seventh Clinical Medical College of Guangzhou University of Traditional Chinese Medicine, Shenzhen, 518133, People's Republic of China.
- Department of Andrology, Shenzhen Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen, 518033, People's Republic of China.
- Department of Andrology, Shenzhen Bao'an Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen, 518133, People's Republic of China.
ORCID-Profile: Wei Fu
Zitieren
APA
Zhang, Q., Liu, C., Wu, S., Zhong, N., Qiu, J., Fu, W., & You, X. (2026). An E3 Aptamer-Modified T Cell-Derived Exosomal Nanoplatform for Codelivery of Astragaloside IV and PESV: Enhancing Prostate Cancer Therapy Through Immune Modulation with Implications for Clinical Translation. International Journal of Nanomedicine, Volume 21, 1-23. https://doi.org/10.2147/ijn.s614400
Vancouver
Zhang Q, Liu C, Wu S, Zhong N, Qiu J, Fu W, et al. An E3 Aptamer-Modified T Cell-Derived Exosomal Nanoplatform for Codelivery of Astragaloside IV and PESV: Enhancing Prostate Cancer Therapy Through Immune Modulation with Implications for Clinical Translation. International Journal of Nanomedicine. 2026;Volume 21:1-23. doi:10.2147/ijn.s614400
BibTeX
@article{Zhang2026,
author = {Zhang, Qing and Liu, Chenguang and Wu, Sirui and Zhong, Nan and Qiu, Junfeng and Fu, Wei and You, Xujun},
title = {An E3 Aptamer-Modified T Cell-Derived Exosomal Nanoplatform for Codelivery of Astragaloside IV and PESV: Enhancing Prostate Cancer Therapy Through Immune Modulation with Implications for Clinical Translation},
journal = {International Journal of Nanomedicine},
year = {2026},
volume = {Volume 21},
pages = {1--23},
doi = {10.2147/ijn.s614400}
}
EUVIMED